Masaki Kato

List of Publications by Year
in descending order

72	2,711	257450 24	189892 50
papers	citations	h-index	g-index

75	75	75	3468
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Divergence of doseâ€“response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. CNS Spectrums, 2022, 27, 369-377.	1.2	2
2	Differences in prescription patterns between real-world outpatients with bipolar I and II disorders in the MUSUBI survey. Asian Journal of Psychiatry, 2022, 67, 102935.	2.0	9
3	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. World Journal of Biological Psychiatry, 2022, 23, 785-793.	2.6	6
4	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International Journal of Molecular Sciences, 2022, 23, 3873.	4.1	8
5	Relationship Between Employment Status and Unstable Periods in Outpatients with Bipolar Disorder: A Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI) Study. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 801-809.	2.2	5
6	Determinants of three-year clinical outcomes in real-world outpatients with bipolar disorder: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI). Journal of Psychiatric Research, 2022, 151, 683-692.	3.1	5
7	Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission. Neuropsychopharmacology Reports, 2022, 42, 306-314.	2.3	6
8	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8Âweeks. Journal of Affective Disorders, 2022, 314, 27-33.	4.1	4
9	Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry, 2021, 26, 118-133.	7.9	71
10	Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study. Human Psychopharmacology, 2021, 36, e2764.	1.5	11
11	Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2867-2876.	2.2	6
12	Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry, 2021, 54, 60-67.	3.3	10
13	Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder. PLoS ONE, 2021, 16, e0262129.	2.5	5
14	Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: A multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). Journal of Psychiatric Research, 2020, 131, 228-234.	3.1	15
15	Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. BMC Psychiatry, 2020, 20, 555.	2.6	16
16	Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. Journal of Psychiatric Research, 2020, 129, 160-167.	3.1	7
17	Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disorders, 2020, 22, 822-830.	1.9	16
18	Pharmacological management of depression: Japanese expert consensus. Journal of Affective Disorders, 2020, 266, 626-632.	4.1	30

#	Article	IF	Citations
19	Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI) . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 881-890.	2.2	21
20	Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. Clinical Psychopharmacology and Neuroscience, 2020, 18, 599-606.	2.0	16
21	Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3Î² Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder. Neuropsychobiology, 2019, 78, 136-144.	1.9	4
22	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and metaâ€analysis of doubleâ€blind, randomized, placeboâ€controlled trials with an enrichment design. Neuropsychopharmacology Reports, 2019, 39, 241-246.	2.3	10
23	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. Journal of Neural Transmission, 2019, 126, 35-45.	2.8	27
24	Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurology, 2018, 75, 842.	9.0	52
25	The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression. Journal of Affective Disorders, 2018, 233, 15-20.	4.1	71
26	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 65.	2.6	38
27	Sevoflurane anesthesia in electroconvulsive therapy: a meta-analysis of randomized controlled trials. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-90.	0.0	0
28	PGx in Depression, Current Status and Future Prospects for Clinical Use. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, JSCPT-FS-3.	0.0	0
29	Estimated cognitive decline in patients with schizophrenia: A multicenter study. Psychiatry and Clinical Neurosciences, 2017, 71, 294-300.	1.8	51
30	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research, 2017, 89, 97-104.	3.1	17
31	Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. Neuropsychobiology, 2017, 75, 81-88.	1.9	19
32	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv125.	2.1	26
33	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry, 2016, 16, 172.	2.6	16
34	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 27-31.	1.4	11
35	Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 703-717.	3.2	24
36	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology, 2016, 73, 35-42.	1.9	21

#	Article	IF	Citations
37	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. Neuropsychobiology, 2015, 72, 118-125.	1.9	8
38	Efficacy of aripiprazole augmentation in <scp>J</scp>apanese patients with major depressive disorder: A subgroup analysis and Montgomeryâ€“Ã…sberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry and Clinical Neurosciences, 2015, 69, 34-42.	1.8	24
39	Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 414-423.	1.3	7
40	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 220-227.	1.4	22
41	Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression. Neuropsychiatric Disease and Treatment, 2015, 11, 435.	2.2	2
42	Changes in energy during treatment of depression: an analysis of duloxetine in doubleâ€blind placeboâ€controlled trials. International Journal of Clinical Practice, 2015, 69, 1139-1148.	1.7	6
43	Antagonist and partial agonist at the dopamine D2 receptors in drug-naÃ¯ve and non-drug-naÃ¯ve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 579-588.	3.2	5
44	The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translational Psychiatry, 2015, 5, e553-e553.	4.8	107
45	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational Psychiatry, 2015, 5, e513-e513.	4.8	20
46	Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression. CNS Drugs, 2013, 27, 11-19.	5.9	45
47	Management of Chronic Depressive Patients with Residual Symptoms. CNS Drugs, 2013, 27, 53-57.	5.9	12
48	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Review of Neurotherapeutics, 2013, 13, 851-870.	2.8	83
49	A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 110-114.	4.8	13
50	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2013, 33, 131-132.	1.4	12
51	Prediction of Treatment Response in Depression Based on Genetic Factors from the Practical Viewpoint. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 117-122.	0.1	0
52	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2012, , 1.	1.4	1
53	Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Research, 2012, 198, 424-429.	3.3	23
54	Differences in quantitative EEG between frontotemporal dementia and Alzheimerâ€™s disease as revealed by LORETA. Clinical Neurophysiology, 2011, 122, 1718-1725.	1.5	69

#	Article	IF	Citations
55	Olfactory reference syndrome treated by blonanserin augmentation. Psychiatry and Clinical Neurosciences, 2011, 65, 203-204.	1.8	3
56	ï¼’ï¼ŽæŠ—ã‡ãè–¬ã®åå¿œäº^æ¸¬å›åã¨ã•–ã¦ã®è–¬ç‡é²ä¼å¦ çš„ã‚¢ãƒ—ãƒãƒ¼ãƒã®å•èƒ½æ€§. Japanese Journal of Clinical Pharmacolog	0.1	0
57	Syndrome of inappropriate secretion of antiâ€diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. International Journal of Geriatric Psychiatry, 2010, 25, 433-434.	2.7	9
58	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry, 2010, 15, 473-500.	7.9	405
59	Effect of 5â€HT1A gene polymorphisms on antidepressant response in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 115-123.	1.7	89
60	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry and Clinical Neurosciences, 2009, 63, 322-328.	1.8	15
61	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Research, 2009, 167, 97-105.	3.3	25
62	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European Neuropsychopharmacology, 2009, 19, 718-725.	0.7	24
63	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 398-404.	4.8	126
64	Antidepressant response and intolerance to SSRI is not influenced by G-protein Î²3 subunit gene C825T polymorphism in Japanese major depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1041-1044.	4.8	29
65	The serotonin transporter gene and effectiveness of SSRIs. Expert Review of Neurotherapeutics, 2008, 8, 111-120.	2.8	24
66	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics Journal, 2008, 8, 90-100.	2.0	74
67	The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran. Journal of Clinical Psychopharmacology, 2008, 28, 518-524.	1.4	30
68	Delirium Associated with Paroxetine in an Elderly Depressive Patient: A Case Report. Pharmacopsychiatry, 2007, 40, 199-200.	3.3	8
69	No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression. Neuropsychobiology, 2007, 56, 167-171.	1.9	29
70	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry, 2007, 12, 247-257.	7.9	487
71	Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. Neuropsychobiology, 2006, 53, 186-195.	1.9	143
72	Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International Clinical Psychopharmacology, 2005, 20, 151-156.	1.7	74